IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
36.20
+0.19 (0.53%)
Jan 22, 2026, 4:00 PM EST - Market closed
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
The 12 analysts that cover IDEAYA Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $49.67, which forecasts a 37.21% increase in the stock price over the next year. The lowest target is $30 and the highest is $79.
Price Target: $49.67 (+37.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IDEAYA Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 4 | 5 |
| Buy | 8 | 11 | 11 | 9 | 9 | 8 |
| Hold | 1 | 1 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 15 | 17 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $41 → $45 | Buy | Maintains | $41 → $45 | +24.31% | Jan 21, 2026 |
| UBS | UBS | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +38.12% | Jan 7, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $59 → $60 | Strong Buy | Maintains | $59 → $60 | +65.75% | Jan 6, 2026 |
| Truist Securities | Truist Securities | Strong Buy Initiates $59 | Strong Buy | Initiates | $59 | +62.98% | Nov 24, 2025 |
| Mizuho | Mizuho | Buy Maintains $44 → $46 | Buy | Maintains | $44 → $46 | +27.07% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
195.19M
from 7.00M
Increased by 2,688.43%
Revenue Next Year
52.21M
from 195.19M
Decreased by -73.25%
EPS This Year
-1.42
from -3.36
EPS Next Year
-3.66
from -1.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 288.8M | 176.4M | ||||
| Avg | 195.2M | 52.2M | ||||
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 4,025.0% | -9.7% | ||||
| Avg | 2,688.4% | -73.3% | ||||
| Low | 40.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.79 | -2.43 | ||||
| Avg | -1.42 | -3.66 | ||||
| Low | -3.46 | -4.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.